Pharmaceutical

UK MHRA approves AbbVie’s migraine prevention drug Aquipta

The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant) for the prophylaxis of migraine in adults.

Sep 5, 2023 - 20:00
UK MHRA approves AbbVie’s migraine prevention drug Aquipta
The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant) for the prophylaxis of migraine in adults.
Read the original article

Tags:

Previous Article

Cipla to bolster OTC portfolio with acquisition of Actor Pharma

Next Article

Chinese NMPA approves AstraZeneca’s Calquence for leukaemia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Jay Bradner, former Novartis research leader, to head up Amgen’s scientific efforts

STAT+: Jay Bradner, former Novartis research leader, to...

Dec 15, 2023

STAT+: AstraZeneca sues to stop Medicare drug price negotiation program

STAT+: AstraZeneca sues to stop Medicare drug price neg...

Aug 25, 2023

Recursion and Exscientia merge to form drug discovery company

Recursion and Exscientia merge to form drug discovery c...

Aug 11, 2024